Contents

I. Innovation: Key to Success in the Pharmaceutical Industry......1
   The Productivity Paradox .................................................................1
   The Blockbuster Imperative ............................................................4
   High Risks in Drug Development ................................................10
   Strategies for Growth ....................................................................12
   Differentiation via Clinical Profiles .............................................15
   Entering the Market Quickly ......................................................16
   Conclusions .................................................................................17

II. The Industry Challenge: Do You Really Want to Be in This Business? ................................................................. 19
   High Complexity of the Industry ....................................................19
   How Attractive is the Pharmaceutical Industry? ............................22
   Force 1: Bargaining Power of Suppliers ........................................24
   Force 2: Bargaining Power of Buyers ..........................................25
   Force 3: Risk of Entry from Potential Competitors ....................26
   Force 4: Threat of Substitute Products ........................................27
   Force 5: Rivalry among Established Companies ..........................28
   Force 6: The Regulators ...............................................................28
   Conclusions ..................................................................................30

III. The Science and Technology Challenge: How to Find New Drugs ...........................................................................33
   Rise of the Biotechnology Industry: Boosting Innovation ..........33
   High-Throughput Screening: Fail Earlier, Succeed Sooner ..........38
   Combinatorial Chemistry: Cut Experimental Cycle Times ..........39
   Bioinformatics: More than 100 Gigabytes of Data per Day .........40
   Proteomics: Profiting from the Human Genome Project ............42
   Genomics: Towards Individualization and Mass Customization ...43
   Pharmacogenomics: Create Tailor-made Drugs ......................45
   Molecular Design: From Experimenting to Analytic Design ..........47
   Conclusions .................................................................................48
IV. The Pipeline Management Challenge: How to Organize Innovation ..................................................................................................................51

The Relevance of Pipeline Management ..................................................51
Complexity and Phases of the R&D Process .......................................56
The Importance of Project and Portfolio Management .....................65
The Disaggregation of the Pharmaceutical Value Chain ....................68
Impact of Outsourcing on Pharmaceutical R&D ............................71
Rising Importance of R&D Collaborations ......................................75
Research Alliances: Accessing Early-stage Innovation .......................78
In-licensing: Enhancing the Innovation Pipeline ...............................81
Co-development: Mutually Benefiting from Joint Resources .............83
Out-licensing: Commercializing Internal Research Results ..........86
How to Commercialize a Breakthrough Technology .......................95
Conclusions ........................................................................................100

V. The Internationalization Challenge: Where to Get Access to Innovation ........................................................................................................103

Trends and Drivers of R&D Internationalization ............................103
Primary Locations of Pharmaceutical R&D around the World .......108
New Opportunities for Drug Development in China .......................111
Three Principal Problems of Dispersed R&D ..................................117
Conclusions ........................................................................................121

VI. Management Answers to Pharmaceutical R&D Challenges ....123

Managing R&D Organization at Roche ..............................................123
Managing R&D Strategy at Schering ..................................................125
Managing the Research-to-Development Handover at Roche .......127
Managing Outsourcing Activities at Solvias ....................................130
Managing Intellectual Property Rights at Bayer ..............................133
Managing Out-licensing at Novartis ...............................................137
Managing Uncertainty at Roche .......................................................144
Managing Global R&D at Major Swiss Pharma Companies ...........145
Managing a Niche-Market Strategy at Intarcia ................................151
Managing Virtual Project Management Pools at Roche .................153
Conclusions .......................................................................................156

VII. Future Directions and Trends ....................................................159
<table>
<thead>
<tr>
<th>Contents</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bibliography</td>
<td>165</td>
</tr>
<tr>
<td>Index</td>
<td>173</td>
</tr>
<tr>
<td>Glossary</td>
<td>179</td>
</tr>
<tr>
<td>Authors</td>
<td>185</td>
</tr>
</tbody>
</table>
Leading Pharmaceutical Innovation
Trends and Drivers for Growth in the Pharmaceutical Industry
Gassmann, O.; Reepmeyer, G.; von Zedtwitz, M.
2008, XVI, 186 p. 47 illus., Hardcover
ISBN: 978-3-540-77635-2